TD Cowen maintains Purchase on Seres, cites optimistic examine information By Investing.com
On Thursday, TD Cowen expressed continued confidence in Seres Therapeutics (NASDAQ:), sustaining…
Longboard Prescription drugs Broadcasts Optimistic Interim Evaluation Outcomes from the Open-Label Extension (OLE) of the Part 1b/2a PACIFIC Examine Evaluating Bexicaserin in Members with Developmental and By Investing.com
Bexicaserin achieved an general median seizure discount of 57.7% in countable motor…
China’s lending to Africa rises for first time in seven years, research reveals By Reuters
By Duncan Miriri NAIROBI (Reuters) -Chinese language lenders accredited loans value $4.61…
Yunovia Pronounces IND Approval by the MFDS to Provoke Section 1 MAD Examine for the Small Molecule GLP-1 Agonist By Investing.com
SEOUL, South Korea, Aug. 27, 2024 /PRNewswire/ -- Yunovia, a drug R&D…
Research outcomes from section 1 research with exidavnemab printed in The Journal of Medical Pharmacology By Investing.com
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA…
Senhwa Biosciences receives US FDA Examine Might Proceed letter for the Part I/II examine of Silmitasertib (CX-4945) together with chemotherapy in kids and younger adults with relapsed refractory s By Investing.com
TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc.…
Scotiabank sees ‘deep worth’ in Sage Therapeutics inventory regardless of research setback By Investing.com
On Wednesday, Scotiabank adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE), decreasing the…
Camurus proclaims constructive Part 3 outcomes from the ACROINNOVA 2 examine of octreotide SC depot (CAM2029) in acromegaly sufferers By Investing.com
Therapy nicely tolerated with a security profile in line with standard-of-care (SoC)Elevated…
